Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-01-14FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application for levetiracetam from Lupin Pharmaceuticals, Inc., related to the generic product.
-
FDA approval · 2016-01-13FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for gabapentin from Actavis Pharma, Inc., updating the approval status for this generic product.
-
CLINICAL_TRIALS trial_result · 2016-01-11Clinical Trial Update: A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures [Phase 3]
Phase 3 trial evaluating adjunctive perampanel for primary generalized tonic-clonic seizures has completed; results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-01-11Clinical Trial Update: Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices [NA]
A completed clinical trial evaluated the effectiveness of low-cost devices in improving patient adherence across multiple conditions. The up…
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: Open Label, Zonegran (Zonisamide) In Partial Onset Seizures [Phase 4]
Phase 4 open-label study of Zonegran (zonisamide) for partial onset seizures has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-01-06FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc. The approval per…
-
FDA approval · 2016-01-04FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Dr. Reddy's Laboratories Ltd)
The FDA approved a supplemental application for divalproex sodium submitted by Dr. Reddy's Laboratories Ltd.
-
CLINICAL_TRIALS trial_result · 2016-01-01Clinical Trial Update: Dietary Therapy in Children With Refractory Epilepsy [Phase 2]
Phase 2 clinical trial evaluating dietary therapy for children with refractory epilepsy has completed.
-
CLINICAL_TRIALS trial_result · 2016-01-01Clinical Trial Update: Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates [Phase 4]
Phase 4 clinical trial comparing oral 30% dextrose to intravenous midazolam for sedation during MRI in neonates; current status is unknown.
-
CLINICAL_TRIALS research · 2015-12-31Clinical Trial Update: Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy [NA]
An ongoing University of Sao Paulo trial is evaluating how a ketogenic diet affects lipoprotein levels in patients with refractory epilepsy,…
-
FDA approval · 2015-12-26FDA Approved: VALPROIC ACID — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for valproic acid from Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2015-12-24Clinical Trial Update: Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy
A completed clinical trial evaluating the effects of adjunctive lacosamide on mood states and quality of life in people with epilepsy.
-
FDA approval · 2015-12-23FDA Approved: LAMOTRIGINE — Supplemental Application (Advagen Pharma Limited)
FDA approved a supplemental application for lamotrigine by Advagen Pharma Limited, documenting the approved generic lamotrigine product unde…
-
FDA approval · 2015-12-23FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) by Supernus Pharmaceuticals, Inc.
-
FDA approval · 2015-12-23FDA Approved: GABAPENTIN — Original Application (Ascend Laboratories, LLC)
FDA approved the gabapentin original application for Ascend Laboratories, LLC, enabling a generic version of gabapentin.
-
CLINICAL_TRIALS trial_result · 2015-12-21Clinical Trial Update: Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic [Phase 3]
Phase 3 trial evaluating safety and efficacy of eslicarbazepine monotherapy in patients with partial epilepsy not well controlled by current…
-
CLINICAL_TRIALS trial_result · 2015-12-15Clinical Trial Update: A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures [Phase 2]
Clinical trial evaluating safety and pharmacokinetics of lacosamide in children with partial seizures (Phase 2; completed; results posted).
-
FDA approval · 2015-12-14FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Levetiracetam from Prasco Laboratories, resulting in updated labeling for this antiepileptic…
-
FDA approval · 2015-12-11FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Lamotrigine submitted by Zydus Pharmaceuticals USA Inc., authorizing changes to the product …
-
CLINICAL_TRIALS trial_result · 2015-12-10Clinical Trial Update: 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures [Phase 2]
The four-year open-label extension of a Phase 2 study evaluating E2007 in patients with refractory partial seizures has completed, and resul…
-
CLINICAL_TRIALS trial_result · 2015-12-08Clinical Trial Update: EEG@HOME (Phase 1 of the Project) [NA]
Phase 1 clinical trial update for the EEG@HOME project focusing on epilepsy has been completed.
-
FDA approval · 2015-12-04FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) submitted by Supernus Pharmaceuticals, indicating an approved update…
-
CLINICAL_TRIALS trial_result · 2015-12-04Clinical Trial Update: Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures [Phase 3]
An open-label Phase 3 study evaluated the safety and tolerability of intravenous lacosamide in Japanese adults with partial-onset seizures; …
-
FDA approval · 2015-11-30FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Zydus Pharmaceuticals USA Inc. The specific changes covered by th…
-
FDA approval · 2015-11-30FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' supplemental application for Divalproex Sodium under ANDA078239, granting approval of a generic product…